The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


IPV-Boostrix– Suspension for injection in a pre-filled syringeDiphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content)



GlaxoSmithKline (Ireland) LimitedPA1077/101/001

Main Information

Trade NameIPV-Boostrix– Suspension for injection in a pre-filled syringeDiphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content)
Active SubstancesDiphtheria toxoid
Tetanus toxoid
Pertussis toxoid
Filamentous haemagglutinin (fha)
Pertactin
Type 1 (mahoney)
Type 2 (mef-1)
Type 3 (saukett)
Dosage FormSuspension for injection in pre-filled syringe
Licence HolderGlaxoSmithKline (Ireland) Limited
Licence NumberPA1077/101/001

Group Information

ATC CodeJ07CA02 diphtheria-pertussis-poliomyelitis-tetanus

Status

License statusAuthorised
Licence Issued10/12/2004
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceBatches of Vaccine marketed in Ireland shall be subject to control authority batch release in accordance 114.1 of Directive 2001/83/EC.
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back